The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A ...

AstraZeneca (AZN) and Daiichi Sanyko (DSKYF)(DSNKY) said the FDA has accepted their application with priority review for ...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the ...

Jennifer McNeill claimed she visited her GP and A&E several times, but was told it was muscular. A mum who struggled to lift ...

As the nights draw in Bryony Fernandez is preparing for the next phase of helping her fiancé, Jon Ward, to access the ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their cancer drug Enhertu received a priority review by the Food & Drug Administration in the US for some forms of breast ...

(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or ...

The success of Daiichi Sankyo's Enhertu, particularly for a variety of HER2-overexpressed cancer types, was highlighted as a significant achievement. The recent approval by the FDA of Enhertu for ...

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.